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Marked tGf-β-regulated miRnA 
expression changes in both copD 
and control lung fibroblasts
J. ong1,2, A. faiz2,3,4, W. timens  1,2, M. van den Berge  2,3, M. M. terpstra5, K. Kok5,  
A. van den Berg1, J. Kluiver1,6 & c. A. Brandsma  1,2,6*
COPD is associated with disturbed tissue repair, possibly due to TGF-β-regulated miRnA changes in 
fibroblasts. Our aim was to identify TGF-β-regulated miRNAs and their differential regulation and 
expression in COPD compared to control fibroblasts. Small RNA sequencing was performed on TGF-β-
stimulated and unstimulated lung fibroblasts from 15 COPD patients and 15 controls. Linear regression 
was used to identify TGF-β-regulated and COPD-associated miRNAs. Interaction analysis was 
performed to compare miRNAs that responded differently to TGF-β in COPD and control. Re-analysis of 
previously generated Ago2-IP data and Enrichr were used to identify presence and function of potential 
target genes in the miRNA-targetome of lung fibroblasts. In total, 46 TGF-β-regulated miRnAs were 
identified in COPD and 86 in control fibroblasts (FDR < 0.05). MiR-27a-5p was the most significantly 
upregulated miRNA. MiR-148b-3p, miR-589-5p and miR-376b-3p responded differently to TGF-β in 
COPD compared to control (FDR < 0.25). MiR-660-5p was significantly upregulated in COPD compared 
to control (FDR < 0.05). Several predicted targets of miR-27a-5p, miR-148b-3p and miR-660-5p were 
present in the miRNA-targetome, and were mainly involved in the regulation of gene transcription. In 
conclusion, altered TGF-β-induced miRNA regulation and differential expression of miR-660-5p in COPD 
fibroblasts, may represent one of the mechanisms underlying aberrant tissue repair and remodelling in 
copD.
Chronic obstructive pulmonary disease (COPD) is characterized by a variable extent and combination of (small) 
airway disease and emphysema. It is a major and still growing cause of death worldwide1,2. One of the features 
underlying the development of COPD is aberrant tissue repair and remodelling3, leading to a disturbed extracel-
lular matrix (ECM) homeostasis. In COPD patients, narrowing of the (small) airways is observed, due to airway 
wall fibrosis4. In contrast, proper tissue repair is diminished in the parenchyma contributing to the develop-
ment of pulmonary emphysema4,5. Malfunction of lung fibroblasts through dysregulation of the TGF-β signalling 
pathway may be pivotal to this aberrant tissue repair and remodelling5. Lung fibroblasts are the principal cells 
in controlling ECM homeostasis by producing ECM proteins, matrix metalloproteases and tissue inhibitors of 
matrix metalloproteases. Transforming growth factor-β (TGF-β) is the main inducer of ECM production in lung 
fibroblasts. TGF-β levels are increased in COPD5–8 and alterations in the TGF-β signalling pathway have been 
demonstrated in COPD compared to control fibroblasts9.
MicroRNAs (miRNAs) regulate the vast majority of cellular processes and pathways by negatively influencing 
protein expression of multiple target genes10. These small non-coding RNAs play a role in various human dis-
eases11. Several studies suggested that miRNAs contribute to COPD pathogenesis based on differential expres-
sion in e.g. whole blood, bronchoalveolar lavage cell fraction and lung tissue from COPD patients compared to 
smoking controls12,13. Previously, Ikari et al. compared miRNA expression changes between COPD and con-
trol fibroblasts (n = 5 per group)14 and selected miR-503, which was decreased in COPD fibroblasts, for further 
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validation15. MiR-503 was demonstrated to enhance the production of VEGF, a direct target of miR-50315. Apart 
from these findings on miRNA expression in lung fibroblasts, limited information on differential miRNA expres-
sion in COPD fibroblasts is available. In our previous study, we identified 29 TGF-β-regulated miRNAs in pri-
mary parenchymal lung fibroblasts from control subjects16. Of these miRNAs, miR-455-3p and miR-21-3p were 
shown to target genes that are involved in the TGF-β and WNT signalling pathways, indicating a role of these 
miRNAs in tissue repair16. We hypothesize that TGF-β-regulated changes in miRNA expression in lung fibro-
blasts are involved in the pathogenesis of COPD.
To better understand the alterations in the TGF-β-regulated tissue repair response in COPD, it is of interest 
to identify miRNAs that are regulated by TGF-β in COPD and control lung fibroblasts and to identify miRNAs 
that are differentially regulated by TGF-β in COPD compared to control fibroblasts. In the present study, we 
used small RNA sequencing analysis; (1) to identify TGF-β-regulated miRNAs in clinically well-characterized 
severe COPD and control fibroblasts, (2) to identify which miRNAs are differentially regulated by TGF-β between 
COPD and control fibroblasts and (3) to determine miRNAs differentially expressed between COPD and control 
fibroblasts.
Results
Subject characteristics. Clinical characteristics of the 30 lung fibroblast and 35 lung tissue donors are 
shown in Table 1. Six of the lung fibroblasts donors in the control group were current smokers. The other 24 lung 
fibroblasts donors and all lung tissue donors were ex-smokers. No differences were identified in age and number 
of pack-years between controls and COPD patients, and also not between lung fibroblast and lung tissue donors.
Differentially expressed miRNAs in response to TGF-β stimulation. As a control of successful 
TGF-β stimulation we first analysed the expression of fibronectin-1 (FN1), collagen type I alpha I (COL1A1), 
and alpha-smooth muscle actin (α-SMA), three known TGF-β-induced genes. A significant upregulation was 
observed for all three genes in both COPD and control fibroblasts (Supplementary Figure 1, p < 0.001). The total 
number of reads obtained of each sample and the percentages of reads mapping to miRBase Release 21 are shown 
in Supplementary Table 1. The ten most abundant miRNAs (Fig. 1) were expressed at similar levels in lung fibro-
blasts from control and COPD fibroblasts, either with or without TGF-β stimulation. The majority of the reads 
in all four groups were derived from miR-21-5p. Together, the top-10 most abundant miRNAs accounted for 
approximately 65% of all reads in unstimulated and TGF-β-stimulated lung fibroblasts (Fig. 1).
Next, we identified miRNAs that were differentially expressed upon TGF-β stimulation in lung fibroblasts 
from controls and COPD patients. In control subjects, we identified 86 differentially expressed miRNAs (49 up- 
and 37 downregulated, FDR < 0.05, Fig. 2A, Supplementary Table 2). In COPD patients, 46 miRNAs were differ-
entially expressed upon TGF-β stimulation (33 up- and 13 downregulated, FDR < 0.05, Fig. 2B, Supplementary 
Table 2). The overlap between the control and COPD fibroblasts was 27 for the TGF-β-induced and 9 for the 
TGF-β-repressed miRNAs (Fig. 2C,D). In total, 96 miRNAs were significantly differentially expressed upon 
TGF-β stimulation in lung fibroblasts of controls and/or COPD patients, including the most abundantly expressed 
miRNAs miR-21-5p, miR-26a-5p, miR-221-3p and miR-222-3p (Supplementary Table 2). The most significantly 
differentially expressed miRNA for both groups was miR-27a-5p with a fold change of 4.1 in control and 3.0 in 
COPD fibroblasts (Fig. 2E). The TGF-β-induced differential expression of miR-27a-5p was validated in the same 
lung fibroblasts using RT-qPCR (p-value < 0.001, Fig. 2F).
MiRNAs differentially regulated by TGF-β in COPD compared to control fibroblasts. To iden-
tify miRNAs that are differentially regulated by TGF-β in COPD compared to control fibroblasts, we performed 
an interaction analysis on the 96 TGF-β-regulated miRNAs identified above. We found twelve miRNAs that 
responded differentially to TGF-β stimulation in lung fibroblasts from COPD compared to control fibroblasts at 
a nominal p-value < 0.05 (Table 2). For seven of them, the change in expression induced by TGF-β was detected 
only in control fibroblasts while there was no change in COPD fibroblasts. For two miRNAs, an increased expres-
sion was observed in COPD upon TGF-β treatment, while there was no change in control fibroblasts. Three 
miRNAs showed a change in the same direction, but in different degrees.
Characteristics
Lung fibroblast donors Lung tissue donors
Controls COPD patients Controls COPD patients
N 15 15 17 18
Male/Female, n 7/8 6/9 8/9 6/12
Age (range), yearsa 65 (50–68) 57 (52–59) 59 (53–70) 55 (52–60)
Ex-/ current smoker, n 9/6 15/0 17/0 18/0
FEV1, %predicteda,b 94.7 (89.4–98.1) 18.4 (15.0–22.3) 89.2 (85.0–99.0) 16.0 (13.8 -23.5)
FEV1/FVC, %a,c 75.8 (72.5–79.1) 24.9 (20.5–28.7) 75.0 (70.2–79.0) 27.8 (26.2–36.0)
Pack-years, na 32.5 (23.3–48.3) 37.5 (30.0–43.3) 32.0 (10.0–43.0) 30.0 (20.4–36.3)
Table 1. Subject characteristics. aMedian (Interquartile range). bFEV1, % predicted, percentage of Forced 
Expiratory Volume in one second of the predicted normal value for an individual of the same sex, age and 
height. cFEV1/FVC, Forced Expiratory Volume in one second/Forced Vital Capacity ratio expressed in 
percentage, a measurement for obstruction in the lungs.
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After correcting for multiple testing, three miRNAs, miR-148b-3p, miR-589-5p and miR-376b-3p, remained 
significant at an FDR < 0.25 (Fig. 3). MiR-148b-3p and miR-589-5p levels were significantly decreased upon 
TGF-β stimulation in control fibroblasts, whereas no effect was observed in COPD fibroblasts. The levels of miR-
376b-3p were significantly increased upon TGF-β stimulation in control fibroblasts, while again no change was 
observed in COPD fibroblasts. Despite reasonable read counts for miR-148b-3p, RT-qPCR revealed very high Cp 
values (34–37), precluding a reliable validation (data not shown). MiR-589-5p and miR-376b-3p had low read 
counts and were therefore not selected for RT-qPCR validation.
Small RNA sequencing analysis of COPD and control lung fibroblasts. Linear regression analysis 
of the 349 miRNAs obtained after filtering revealed one miRNA with a higher expression in lung fibroblasts 
from COPD patients at an FDR cut-off <0.05 (miR-660-5p, FC = 1.4, FDR p-value = 5.9 × 10−3, Fig. 4A,B). 
Additionally, 37 other miRNAs showed differential expression between COPD and control fibroblasts at a nomi-
nal p-value < 0.05 (Supplementary Table 3). Validation of the differential expression of miR-660-5p by RT-qPCR 
in lung fibroblasts was not feasible due to low expression levels (Cp values 33–37, data not shown). In the lung 
tissue samples used for replication, miR-660-5p expression levels were within the range of detection (Cp val-
ues 30–32), however, no differences were observed between lung tissue from COPD patients and from controls 
(Fig. 4C).
Predicted targets of miR-27a-5p, miR-148b-3p and miR-660-5p. For the identification of target 
genes of miR-27a-5p, miR-148b-3p and miR-660-5p relevant in lung fibroblasts we re-analysed our previously 
published miRNA-targetome dataset (generated with Ago2-IP) of primary lung fibroblasts from two control sub-
jects16. For miR-27a-5p a significant enrichment of miRNA target genes in the top-1,500 of most IP-enriched 
genes compared to all expressed genes was observed in one of the two controls (Fig. 5A). For miR-148b-3p, we 
observed a significant enrichment of predicted targets in both controls (p-value < 0.0001, Fig. 5B). For miR-
660-5p, a significant (p-value < 0.05) and a borderline significant (p = 0.0554) enrichment of predicted target 
genes was observed (Fig. 5C).
The top-10 most IP-enriched predicted target genes for each of these three miRNAs are shown in Fig. 5, 
including the ranking in the IP-enrichment for each control. Phosphatidylcholine Transfer Protein (PCTP) was the 
most IP-enriched predicted target gene of the TGF-β-induced miR-27a-5p. Of the most enriched predicted target 
genes of miR-27a-5p, Nuclear Receptor Subfamily 6 Group A Member 1 (NR6A1) and PR/SET Domain 1 (PRDM1) 
are both involved in negative regulation of transcription, and NHL Repeat Containing 3 (NHLRC3) and Trafficking 
Protein Particle Complex 1 (TRAPPC1) are engaged in neutrophil mediated immunity (Supplementary Table 4). 
High Mobility Group AT-Hook 2 (HMGA2) was the most IP-enriched predicted target of miR-148b-3p. Of the 
top-10 most enriched predicted miR-148b-3p target genes, seven genes play a role in the regulation of gene tran-
scription. For miR-660-5p, Solute Carrier Family 46 Member 3 (SLC46A3) and Zinc Finger Protein 273 (ZNF273) 
were the most enriched predicted target genes. Five of the top-10 most IP-enriched predicted miR-660-5p target 
genes were involved in regulation of gene transcription.
Discussion
Using small RNA sequencing, we identified 96 TGF-β-regulated miRNAs in lung fibroblasts from controls and/or 
COPD patients, from which miR-27a-5p was the most strongly TGF-β-induced miRNA. In addition, we identi-
fied miR-148b-3p, miR-589-5p and miR-376b-3p as differentially regulated by TGF-β in COPD compared to con-
trol fibroblasts. Of these miRNAs, only miR-148b-3p was highly expressed based on our small RNA sequencing 
Figure 1. Top-10 most abundant miRNAs in lung fibroblasts of controls and COPD patients with/without 
TGF-β stimulation. Relative fractions of the read counts of the top-10 most abundant miRNAs in unstimulated 
(Left) and in TGF-β-stimulated lung fibroblasts (Right). The read counts in control and COPD lung fibroblasts 
were combined, as the expression levels of these ten miRNAs were similar in control and COPD fibroblasts.
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Figure 2. Differentially expressed miRNAs upon TGF-β stimulation in lung fibroblasts. (A,B) Volcano 
plot of the 349 miRNAs included in the analyses of the small RNA sequencing data. The lowest horizontal 
line represents the nominal p-value cut-off of 0.05. The upper horizontal line represents the FDR of 0.05. 
Differentially expressed miRNAs are indicated with red dots (FDR < 0.05). (C) Overlap of the upregulated 
miRNAs and (D) downregulated miRNAs after TGF-β stimulation in lung fibroblasts from controls and COPD 
patients. (E) MiR-27a-5p expression in the lung fibroblasts from controls and COPD patients with/without 
TGF-β stimulation based on the small RNA sequencing data. ****FDR < 0.0001. (F) Validation of miR-27a-5p 
expression in lung fibroblasts from 15 controls and 12 COPD patients with and without TGF-β stimulation 
using RT-qPCR. The data are presented as relative expression to RNU48 (2−ΔCp). ***p-value < 0.001, 
****p-value < 0.0001.
MiRNA p-value FDR adjusted p-value
Change after TGF-β in
Control COPD
miR-148b-3p 2.57E-03 0.18 −1.3* 1.0
miR-589-5p 5.35E-03 0.18 −1.3* 1.1
miR-376b-3p 5.71E-03 0.18 1.8* 1.1
miR-501-3p 1.39E-02 0.31 −1.4* 1.0
miR-99b-5p 1.67E-02 0.31 1.0 1.2*
miR-27a-5p 2.78E-02 0.31 4.1* 3.0*
miR-25-3p 3.18E-02 0.31 −1.3* 1.0
miR-370-5p 3.67E-02 0.31 1.1 1.5*
miR-136-3p 4.14E-02 0.31 1.3* 1.1
miR-21-3p 4.31E-02 0.31 2.1* 1.7*
let-7e-3p 4.33E-02 0.31 1.3* 1.1
miR-181a-2-3p 4.34E-02 0.31 1.6* 2.0*
Table 2. MiRNAs differentially regulated by TGF-β in COPD compared to control fibroblasts. *Significant 
TGF-β effect.
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data. Furthermore, we demonstrated higher expression of miR-660-5p in COPD compared to control fibroblasts. 
Using our previously published miRNA-targetome dataset, we identified multiple IP-enriched and predicted tar-
gets of miR-27a-5p, miR-148b-3p and miR-660-5p, representing possible targets through which these miRNAs 
may affect lung fibroblast function in COPD.
TGF-β stimulation had a strong effect on the miRNA expression profile in lung fibroblasts from COPD 
patients and controls. Interestingly, we found much less TGF-β-regulated miRNAs in COPD fibroblasts compared 
to controls. A previous study reported that the TGF-β release by COPD fibroblasts was elevated, whereas their 
repair responses were reduced compared to control fibroblasts5. This may suggest that COPD lung fibroblasts are 
also less responsive to TGF-β stimulation in our study. Of the TGF-β-regulated miRNAs, miR-27a-5p was the 
most prominent in lung fibroblasts from both COPD patients and controls. These findings were consistent with 
our previous study investigating TGF-β effects on control lung fibroblasts16. Interestingly, the interaction analysis 
suggested that the induction of miR-27a-5p upon TGF-β stimulation was lower in COPD compared to control 
fibroblasts, supporting the notion that COPD fibroblasts are less responsive to TGF-β than control fibroblasts. 
The most IP-enriched predicted target gene of miR-27a-5p was PCTP. This gene encodes a protein that regulates 
intermembrane transfer of phosphatidylcholine, which is one of the most abundant phospholipids in plasma 
membranes17. Our enrichment and pathway analysis suggest that miR-27a-5p is involved in negative regulation 
of transcription by targeting NR6A1 and PRDM1. NR6A1 can repress gene expression by binding to DNA and 
recruiting DNA methyltransferases18. PRDM1 is a transcription factor that can repress β-interferon expression19. 
In addition, PRDM1 downregulates p53 transcription by binding to its promoter, while p53 positively regulates 
transcription of PRDM120. Knockdown of PRDM1 in human fibroblasts resulted in growth arrest20. Together this 
indicates that TGF-β-induced miR-27a-5p expression in lung fibroblasts may represent a mechanism to control 
TGF-β-induced cell proliferation via targeting PRDM1. Pathway analyses suggested that miR-27a-5p may also 
be involved in neutrophil mediated immunity by targeting NHLRC3 and TRAPPC1. However, expression of 
these genes is not restricted to neutrophils; our previously published Ago2-IP dataset demonstrated high expres-
sion levels of these genes in primary lung fibroblasts16. A recent study showed that miR-27a-5p affected NF-κB 
signalling in human aortic endothelial cells21, but none of those NF-κB signalling genes were enriched in the 
miRNA-targetome of our lung fibroblasts.
Figure 3. TGF-β ~ COPD interaction. Lung fibroblasts of COPD patients responded differently to TGF-β 
stimulation compared to those of controls with respect to expression of miR-148b-3p, miR-589-5p and miR-
376b-3p (p-value miR-148b-3p = 0.0026, p-value miR-589-5p = 0.0053, p-value miR-376b-3p = 0.0057; FDR 
of interaction analysis all <0.25), based on small RNA sequencing data. *FDR TGF-β effect in controls <0.05, 
***FDR TGF-β effect in controls <0.001.
Figure 4. MiR-660-5p in lung fibroblasts and lung tissue from COPD patients. (A) Volcano plot of the 349 
miRNAs included in the analyses of the small RNA sequencing data. The lowest horizontal line represents 
the nominal p-value cut-off of 0.05. The upper horizontal line represents the FDR of 0.05. MiR-660-5p, 
indicated with a red dot, was higher expressed in lung fibroblasts from COPD compared to controls (FC = 1.4, 
FDR = 5.9 × 10−3). (B) MiR-660-5p expression in the lung fibroblasts from controls and COPD patients based 
on the small RNA sequencing data. **FDR = 5.9 × 10−3. (C) MiR-660-5p expression in lung tissue from 
controls and COPD patients using RT-qPCR. The data are presented as relative expression to RNU48 (2−ΔCp).
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In the interaction analyses, we found only miR-148b-3p with high read counts that responded differently at 
an FDR cut-off of 0.25 to TGF-β in lung fibroblasts from COPD patients compared to controls. MiR-148b-3p 
expression was lower upon TGF-β treatment in the controls and did not change in COPD patients. It is tempting 
to speculate that processes are activated in lung fibroblasts from controls in the presence of TGF-β, which may 
contribute to tissue repair and remodelling. This response may be attenuated in lung fibroblasts from COPD 
patients. In bronchial smooth muscle cells from asthma patients, miR-148b-3p was upregulated22. HMGA2 was 
the most IP-enriched target gene of miR-148b-3p and was shown to be required for TGF-β-induced transcription 
of several genes, including GATA623. It was suggested that GATA6 may mediate the TGF-β-induced upregulation 
of alpha-smooth muscle actin (α-SMA) in fibroblasts from idiopathic pulmonary fibrosis with histopathology of 
usual interstitial pneumonia24. As miR-148b-3p was downregulated upon TGF-β-stimulation in lung fibroblasts 
Figure 5. Ago2-IP-enrichment of predicted targets of miR-27a-5p, miR-148b-3p and miR-660-5p. The 
percentages of predicted targets of (A) miR-27a-5p, (B) miR-148b-3p and (C) miR-660-5p were calculated in 
all expressed genes and in the top-1,500 most IP-enriched probes in lung fibroblasts of two control subjects 
(Control 1 and 2). For miR-27a-5p, miR-148b-3p and miR-660-5p, 922, 677 and 421 predicted targets, 
respectively, were included in the analyses. Chi-square test was used to determine whether the number of 
predicted targets in the top-1,500 most Ago2-IP-enriched probes was significantly different from the expected 
based on the number of predicted targets in all expressed genes. All the other numbers in the bars are the 
number of predicted targets of each miRNA. *p-value < 0.05, ****p-value < 0.0001. The top-10 most IP-
enriched predicted target genes are shown in the table. The numbers in the table indicate the rankings of the 
predicted target genes based on the IP-enrichment, i.e. 1 = most IP-enriched predicted target gene, 2 = second 
most IP-enriched target gene.
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from controls, it is plausible that miR-148b-3p may indirectly contribute to the TGF-β-induced upregulation of 
α-SMA. HMGA2 can also induce apoptosis and growth arrest in in human lung fibroblasts25, which may be due 
to the decreased miR-148b-3p expression after TGF-β treatment.
Of the other miRNAs identified in the interaction analysis, miR-99b-5p, miR-181a-2-3p, and miR-136-3p, 
have already been linked to COPD previously26–28. In addition, miR-25-3p and miR-181a-2-3p were found to 
be downregulated in COPD lung fibroblasts compared to controls in our current study (p-value < 0.05). For 
miR-21-3p, we previously showed regulation by TGF-β in control and COPD lung fibroblasts consistent with our 
current findings16.
We found a significantly higher expression of miR-660-5p in lung fibroblasts from COPD patients compared 
to controls. MiR-660-5p did not pop up in the previous miRNA profiling study of Ikari et al.14. Previously, cir-
culating miR-660-5p levels were shown to be positively associated with FEV1/FVC of asthmatic children29. This 
positive association of miR-660-5p with lung function was not found in lung fibroblasts of severe COPD patients 
included in our study. A possible explanation for this might be that this miRNA has cell type and/or organ specific 
functions. Pathway analysis demonstrated that five predicted miR-660-5p targets, including the top gene ZNF273, 
are involved in regulating gene transcription. ZNF273 is a C2H2 zinc-finger motifs and Krüppel-associated box 
(KRAB)-domain-containing protein. Members of the KRAB-containing protein family are involved in transcrip-
tional repression of RNA polymerase promoters, binding and splicing of RNA, and control of nucleolus func-
tion30. In addition, another target, SLC46A3 has been shown to be upregulated in bronchial epithelial cells of 
COPD compared to controls31. This is different from our findings of higher miR-660-5p levels in COPD lung 
fibroblasts, which would rather be associated with lower SLC46A3 expression in COPD. Again, this might be 
due to different involvement in cell type specific functions. Previously, miR-660-5p was shown to directly target 
MDM232, which was among the IP-enriched target gene in one of our controls16. MDM2 is involved in degrada-
tion of p53 protein33 and downregulation of p53 in control lung fibroblasts increased the proliferation rate and 
the migration and invasion capacity33. A miR-660-5p-regulated decrease in MDM2 expression in lung fibroblasts 
may thus modulate fibroblast proliferation and motility via p53. Interestingly, because in line with the increased 
miR-660-5p in COPD, it was reported that p53 protein levels were elevated in emphysematous lung tissue34,35.
Whereas small RNA sequencing revealed differential regulation upon TGF-β stimulation for miR-148b-3p 
in COPD fibroblasts and differential expression of miR-660-5p, both miRNAs could not be validated using 
RT-qPCR in the same samples, since the expression levels were too low to be quantified reliably. Especially for 
miR-148b-3p which had high read counts in the small RNA sequencing data and very strong enrichment of pre-
dicted target genes, this was a surprise. It may be explained by lack of specificity of the assays. Although overall 
read counts of miR-660-5p were relatively low, differences in small RNA sequencing data were clear and signifi-
cant enrichment of predicted target genes in lung fibroblast does suggest that this miRNA is active in these cells. 
Further investigation, including biological validation, is needed to confirm our results.
In conclusion, we showed that TGF-β affects expression of a considerable number of miRNAs in primary 
lung fibroblasts. Three of these TGF-β-regulated miRNAs responded differently to TGF-β in COPD compared 
to control fibroblasts. In contrast, only one miRNA was differentially expressed in COPD fibroblasts. Altered 
miRNA regulation, i.e. differential response to TGF-β stimulation in COPD compared to control fibroblasts and 
differentially expressed miR-660-5p in COPD, may be one of the mechanisms underlying aberrant tissue repair 
and remodelling in COPD.
Materials and Methods
Subjects. The workflow of this study is shown in Fig. 6. Primary fibroblasts were obtained from 15 stage 
IV COPD patients undergoing lung transplant surgery and 15 non-COPD controls with normal lung function 
undergoing lung tumour resection surgery. For the latter group lung fibroblasts were isolated from left-over 
parenchymal lung tissue located far away from the tumour without histological abnormalities36,37. Lung tissue 
from 18 stage IV COPD patients and 17 non-COPD controls was used to replicate the results.
This study was performed in accordance with the national ethical and professional guidelines on the use 
human body material (“Code of conduct; Dutch federation of biomedical scientific societies”; https://www.federa.
org/codes-conduct) and the Research Code of the University Medical Centre Groningen (https://www.umcg.nl/
SiteCollectionDocuments/English/Researchcode/umcg-research-code-2018-en.pdf). The left-over lung material, 
which was used to isolate lung fibroblasts or to replicate the results, was at the time of the experiments not sub-
ject to the act on medical research involving human subjects in the Netherlands. Therefore, an ethics waiver was 
provided by the Medical Ethical Committee of the University Medical Centre Groningen (METc UMCG). All 
samples and clinical information were de-identified before experiments were performed.
Cell culture, TGF-β stimulation and RnA isolation. Primary fibroblasts were isolated from lung paren-
chyma using the explant technique as described previously38. The fibroblasts were cultured in complete medium 
consisting of Ham’s F12 medium, 10% (v/v) fetal calf serum (FCS), 100 U/ml penicillin/streptomycin and 200 
mM L-glutamine (all from Lonza, Breda, The Netherlands). The experiments were performed on fibroblasts at 
passage 5. Lung fibroblasts were stimulated with 7.5 ng/ml TGF-β1 (R&D Systems, Abingdon, UK) in complete 
Ham’s F12 medium containing 0.5% (v/v) FCS for 24 h. Total RNA was isolated from primary parenchymal lung 
fibroblasts and lung tissues using TRIzol (Invitrogen, Carlsbad, CA, USA), according to the protocol of the man-
ufacturer. The RNA concentration was measured with a NanoDrop 1000 Spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA).
cDNA synthesis and qPCR for ECM genes and α-SMA. To confirm effective TGF-β stimulation, 
expression levels of several known TGF-β-regulated genes FN1, COL1A1 and α-SMA in lung fibroblasts39,40 were 
determined by RT-qPCR, as described previously16. 18S rRNA (18S) and RNA polymerase II (RP2) were used as 
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reference genes. Positive and negative controls were included in each run. The formula 2−ΔCp was used to calcu-
late the relative mRNA expression levels.
Small RNA sequencing. Libraries were generated with the NEXTflex Small RNA-seq kit V3 (Bioo Scientific, 
Uden, The Netherlands) using total RNA (approximately 1 μg) of the lung fibroblasts with/without TGF-β stim-
ulation and sequenced on the NextSeq 500 (Illumina, San Diego, CA, USA) according to the protocol of the 
manufacturer. TrimGAlore 0.3.7 was used to trim the adapter sequences of the raw reads. Subsequently, the reads 
were allocated to the human miRNAs (miRBase Release 21, http://www.mirbase.org/) allowing one mismatch 
using the miRDeep2 V2.0.0.8 software41. The reads of miRNAs with the same mature sequence were summed up. 
Only miRNAs with ≥10 reads per million in more than half of the samples in at least one group (lung fibroblasts 
of COPD patients or controls, with or without TGF-β stimulation) were included. After applying these filtering 
steps, 349 miRNAs were left for further analyses.
cDNA syntheses and qPCR for miRNAs. To validate and replicate the small RNA sequencing results, 
RT-qPCR was performed as described previously16,42. Briefly, cDNA was synthesized using 10 ng total RNA of 
the parenchymal fibroblasts and/or lung tissues and reverse transcription primers from TaqMan® microRNA 
Assay kits, small nucleolar RNA, C/D box 48 (RNU48) (Assay ID: 001006), hsa-miR-27a* (Assay ID: 002445), 
hsa-miR-148b (Assay ID: 000471) and efu-miR-660 (Assay ID: 475114_mat) (Applied Biosystems, Carlsbad, CA, 
USA). Assays were selected based on the most abundant miRNA sequence identified in the small RNA sequenc-
ing data. Next, qPCR was performed in LightCycler 480 Probes Master reaction mix (Roche Diagnostics GmbH, 
Mannheim, Germany) and the above mentioned TaqMan microRNA assays. RNU48 was used as reference gene, 
and positive and negative controls were included in each run. The relative miRNA expression levels were calcu-
lated using the formula 2−ΔCp.
Figure 6. Workflow FDR = false discovery rate, DE = differentially expressed, Ago2-IP = argonaute 
2-immunoprecipitation.
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Ago2-IP and gene ontology/pathway analyses. Data of our previously published 
argonaute-2-immunoprecipitation (Ago2-IP) experiments in primary lung fibroblasts from two control subjects 
were used to identify genes targeted by miRNAs selected in this study, as described previously16. Control 1 had 
in total 19,874 expressed genes of which the top-1,500 IP-enriched probes consisted of 1,298 unique genes16. 
Control 2 had in total 17,779 expressed genes of which the top-1,500 IP-enriched probes encounter for 1,306 
unique genes16. For poorly conserved miRNAs, predicted targets with a cumulative weighted context++ score 
≤0.2 were included in the analyses (TargetScan version 7.243). For broadly conserved miRNAs, predicted targets 
with conserved binding sites were considered. To assess the potential functional relevance of individual miR-
NAs, we identified the top-10 most IP-enriched and TargetScan predicted genes. For each miRNA, the top-10 
most enriched predicted target genes were subjected to Enrichr44,45 to identify the biological processes (gene-set 
library: GO_Biological_Process_2018) and Reactome pathways (gene-set library: Reactome_2016). We focused 
on pathways for which at least two of the top-10 enriched genes are involved in, without taking the significance of 
the process/pathway enrichment into account.
Statistical analyses. The Mann Whitney U test was used to compare differences in subject characteristics 
between COPD patients and control subjects, and between the fibroblast and lung tissue donors (IBM SPSS 
Statistics version 22). Small RNA sequencing data were analysed in R (v3.5.2)46 with the Bioconductor-Limma 
package (v3.38.3)47.
Three separate analyses were conducted; (1) a linear regression model (TGF-β - baseline) was performed to 
investigate the effect of TGF-β overall on miRNA expression in controls and COPD fibroblasts, separately, (2) 
interaction analysis ((COPD TGF-β - COPD baseline) - (control TGF-β - control baseline)) was conducted to 
investigate whether miRNAs are differentially regulated by TGF-β in COPD compared to control fibroblasts, and 
(3) a linear regression model (COPD baseline - control baseline) was run to look at the differences of miRNA 
expression between COPD and control fibroblasts at baseline. For the interaction analyses, we focused on miR-
NAs that were differentially expressed upon TGF-β stimulation in fibroblasts from COPD patients and/or con-
trols. These models were adjusted for age, gender, smoking status and library preparation batch. Results were 
corrected for multiple testing using the Benjamini-Hochberg false discovery rate (FDR).
The TGF-β effect on miRNA expression levels determined by RT-qPCR was analysed using the one-sided 
paired Wilcoxon signed rank test. Enrichment of predicted target genes in the Ago2-IP was assessed by a 
chi-square test on the percentage of predicted targets in the top-1,500 enriched probes compared to the percent-
age of predicted targets in all expressed genes. A p-value below 0.05 was considered statistically significant.
Data availability
The small RNA sequencing dataset generated for this manuscript is available for collaboration upon request.
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